aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2024. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company (“aVenture”) is an independent research platform providing information and analysis about startups.
Certain metrics provided by aVenture may seek to assess the risks and opportunities associated with a company, fund, or its representatives (collectively “research”). aVenture seeks to provide this information with objectivity and fairness, and with diligence about its accuracy. Nonetheless, aVenture cannot provide assurance as to the accuracy of the information provided by our research. We strongly advise those using the research platform to seek multiple, independent sources for your research when making financial decisions.
Any links provided to other websites are offered as a matter of convenience and are not intended to imply that aVenture or its authors endorse, sponsor, promote, and/or are affiliated with the owners of or participants in those sites.
The aVenture platform also provides investment listings offered by independent investment advisers in the United States. aVenture is neither a registered investment adviser nor an exempt reporting adviser under the Investment Advisers Act of 1940, and no statements made by aVenture are intended to imply any financial instruments are under the counsel or advice of aVenture or its representatives.
Funds offered on the platform are generally managed by a private investment adviser that, unless stated otherwise, claims exemption from SEC or state registration. Investment funds presented on the platform are only available to investors who meet the requirements of the offering, and solicitations are not made outside those listed jurisdictions.
Additionally, each investment offered on the platform has qualifications for eligibility, including some offered only to Qualified Clients and/or Accredited Investors. Certain funds may be available to non-Qualified or Accredited investors, but only those who become personally known and identifiable to aVenture Investment Company staff, who have had an opportunity to assess the financial capacity and suitability for such an investment, and discuss its risks. Funds, when offered, are only offered following a review of a Private Placement Memorandum (PPM), subscription agreement, and other disclosures.
Investments in startups, venture capital, angel investments, private equity, real estate, stocks, and similar asset classes all involve risks, including: the risk of a decline in the value of your investments, including potentially large declines (suddenly and/or for long periods of time), the potential for illiquidity where part or all of a withdrawal request may not be honored on the date requested (even when a feature of the fund). These risks are heightened during periods of market duress.
Diversification has the possibility of reducing the magnitude of declines (either caused by market/economic factors, or by factors related to the individual company), but does not guarantee these risks have been fully or partially alleviated. Most importantly, past results are not an assurance of future outcomes. While most of these risks are shared and similarly held by other investment asset classes, we recommend investors only consider venture capital investments as part of a broader, diversified portfolio of stocks, bonds, and immediately accessible cash reserves.
From Startups | TechCrunch
By Ron Miller
April 24, 2024
As the notion of the AI agent begins to take hold, and more tasks will be completed without a human involved, it is going to require a new kind of authentication to make sure only agents with the proper approval can access particular resources. Anon, an early stage startup is helping developers add automated authentication in a safe and secure way.
On Wednesday, the company announced a $6.5 million investment — and that the product is now generally available to all.
The founders came up with the idea for this company out of necessity. Their first idea was actually building an AI agent, but CEO Daniel Mason, says they quickly came up against a problem around authentication – simply put, how to enter a username and password automatically and safely. “We kept running into this hard edge of customers wanting us to do X, but we couldn’t do X unless we had this delegated authentication system,” Mason told TechCrunch.
He began asking around about how other AI startups were handling authentication, and found there weren’t really any good answers. “In fact, a lot of the solutions, people that were using, were actually quite a bit less secure. They were mostly inheriting authentication credentials from a user’s local machine or browser-based permissions,” he said.
And as they explored this problem more in depth, they realized that this was in fact a better idea for a company than their original AI agent idea. At this point, they pivoted to becoming a developer tool for building an automated authentication layer designed for AI-driven applications and workflows. The solution is delivered in the form of a software development kit (SDK), and lets developers incorporate authentication for a specific service with a few lines of code. “We want to sit at that authentication level and really build access permissioning, and our customers are specifically the developers,” Mason said.
The company is addressing security concerns about an automated authentication tool from a by working towards building a zero trust architecture where they protect the credentials in a few key ways. For starters, they never control the credentials themselves; those are held by the end user. There is also an encryption layer, where half the key is held by the user and half by Anon, and it requires both to unlock the encryption. Finally, the user always has ultimate control.
“Our platform is such that as a user, when I grant access, I still maintain control of that session – I’m the ultimate holder of the password, user Name, 2FA – and so even in the event of our system, or even a customer system getting compromised, they do not have access to those root credentials,” company co-founder and CTO Kai Aichholz said.
The founders recognize that other companies, large and small, will probably take a stab at solving this problem, but they are banking on a head start and a broad vision to help them stave off eventual competitors. “We’re looking to basically become a one-stop integration platform where you can come and build these actions and build the automation and know that you’re doing it in a way that’s secure and your end user credentials are secure and the automations are going to happen,” Mason said.
The $6.5 investment breaks down into two tranches: a pre-seed of around $2 million at launch and a seed that closed at the end of last year for around $4.5 million. Investors include Union Square Ventures and Abstract Ventures, who led the seed and Impatient Ventures and ex/ante, who led the pre-seed, along with several industry angels.
View original article on techcrunch.com
Share:
Xaira, an AI drug discovery startup, launches with a massive $1B, says it’s ‘ready’ to start developing drugs
Advances in generative AI have taken the tech world by storm. Biotech investors are making a big bet that similar computational methods could revolutionize drug discovery. On Tuesday, ARCH Venture Partners and Foresite Labs, an affiliate of Foresite Capital, announced that they incubated Xaira Therapeutics and funded the AI biotech with $1 billion. Other investors […] © 2024 TechCrunch. All rights reserved. For personal use only.
Apr 25, 2024
Eric Schmidt-backed Augment, a GitHub Copilot rival, launches out of stealth with $252M
AI is supercharging coding — and developers are embracing it. In a recent StackOverflow poll, 44% of software engineers said that they use AI tools as part of their development processes now and 26% plan to soon. Gartner estimates that over half of organizations are currently piloting or have already deployed AI-driven coding assistants, and […] © 2024 TechCrunch. All rights reserved. For personal use only.
Apr 24, 2024
Radical thinks the time has come for solar-powered, high-altitude autonomous aircraft
Though many eyes are on space as orbit develops into a thriving business ecosystem, Radical is keeping things a little closer to the ground — but not too close. Its high-altitude, solar-powered aircraft aim to succeed where Facebook’s infamous Aquila failed by refining the tech and embracing more markets. It’s hard to believe that Facebook’s […] © 2024 TechCrunch. All rights reserved. For personal use only.
Apr 24, 2024
Don't miss our latest news and updates. Subscribe to the newsletter
More from Tech Crunch: